Roth Capital Starts AcelRx Pharmaceuticals (ACRX) at Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/1/2026
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Equity positioning stays overweight, but summer extremes have eased: Barclays
- Oil prices rise by about $1/bbl on stalled US-Iran talks and tight fuel markets
- Micron reports Q4 today: Why Lynx Equity sees massive upside
- Moderna: Citi says oncology optimism is priced in, cuts rating to sell
- Zimbabwe helicopter crash kills six, government spokesperson says
- Apple's iOS 27 is blocking Trade Desk ads on Safari, analyst says
- S&P 500 dips, Nasdaq higher after data shows moderate inflation rise
- Mattel names Roger Lynch as chairman and CEO, replacing Ynon Kreiz
- HPE raises networking revenue outlook, secures $1.2B Vultr order
Jefferies Sees Zalviso Upside for AcelRx (ACRX) Following Pain Survey
April 16, 2014 6:58 AM EDTJefferies analyst Biren Amin reiterated a Buy rating and $17 price target on AcelRx Pharmaceuticals (NASDAQ: ACRX) following a physician survey which offered an optimistic upside scenario for Zalviso.
Amin commented, "We recently surveyed 43 physicians which currently prescribe IV patient-controlled analgesia to their... More
Jefferies Assumes AcelRx Pharmaceuticals (ACRX) at Buy
April 10, 2014 6:33 AM EDTJefferies assumes coverage on AcelRx Pharmaceuticals (NASDAQ: ACRX) with a Buy rating and a price target of $17.00 (from $15.00).
Analyst Biren Amin said, "We expect FDA approval of Zalviso, a treatment for moderate to severe pain in post-surgical patients, on its PDUFA Jul 27... More
